Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Obsidian Therapeutics, Inc. (“Obsidian”) (NASDAQ:OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today reported financial results for the third quarter ended September 30, 2026…